Pharma News, 2024

FibroBiologics has entered a master services agreement with Charles River Laboratories to develop and manufacture cell-based therapies for chronic diseases. The agreement will involve the manufacture ...

PARIS ― The French government said Sunday it is backing the sale of a subsidiary of pharmaceuticals multinational Sanofi that produces over-the-counter drugs to American private equity firm CD&R aft...

New Delhi: Indian pharmaceutical firms are falling behind their global counterparts across key performance indicators, including R&D intensity, the proportion of PhD employees, and the number of paten...

On Friday, Novo Nordisk A/S said that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending approval of...

Zolbetuximab-clzb (Vyloy; Astellas Pharma Inc) was granted FDA approval for the treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-...

Chengdu Baiyu Pharmaceutical Co., Ltd. (Chengdu, China) announced that it has entered into an exclusive license agreement with Novartis for a small molecule anti-tumor asset.

An FDA AdCom in September recommended against full approval for Ocaliva (obeticholic acid) by a 13-1 vote for the treatment of primary biliary cholangitis. The original FDA full approval decis...

On Thursday, Rani Therapeutics Holdings Inc. shares maintained a positive outlook as H.C. Wainwright reaffirmed a Buy rating with a $9.00 price target.

Sagimet Biosciences' Denifanstat shows significant potential in treating MASH, with FDA Breakthrough Therapy designation and peer-reviewed validation, supporting a "Strong Buy" rating. D...

Rectify Pharmaceuticals, Inc., a biotechnology company developing positive functional modulators (PFMs), small molecule therapeutics that restore and enhance membrane protein function, today a...

Amgen has shared positive top-line results from a late-stage trial of its B cell-depleting therapy Uplizna (inebilizumab-cdon) in adults with generalised myasthenia gravis (gMG).

The FDA has accepted the New Drug Application (NDA) for investigational, first-in-class oral antibiotic gepotidacin, according to a press release from manufacturer GSK. The drug, which has a n...